A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Lazertinib Di-N-oxide - Request Quote

Picture of Lazertinib Di-N-oxide

Lazertinib Di-N-oxide

SZ CAT No:SZ-L127013
CAS No
NA
Mol.F.
C30H34N8O5
Mol.Wt.
586.7
Inv. Status
Synthesis on demand

Chemical Name :

Shipping Temperature :

HSN Code :

Country of Origin :

Smiles :

Usage Note:

Lazertinib Di-N-oxide is chemically 1-(1-(2-((5-acrylamido-2-methoxy-4-(4-oxidomorpholino)phenyl)amino)pyrimidin-4-yl)-3-phenyl-1H-pyrazol-4-yl)-N,N-dimethylmethanamine oxide. Lazertinib Di-N-oxide is supplied with detailed characterization data compliant with regulatory guideline. Lazertinib Di-N-oxide can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Lazertinib.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Applications & Regulatory Use Cases

buy high quality Lazertinib Di-N-oxide

Purchase Lazertinib Di-N-oxide

Lazertinib Di-N-oxide suppliers

Lazertinib Di-N-oxide manufacturers

Lazertinib Di-N-oxide price

Order Lazertinib Di-N-oxide

Enquire Lazertinib Di-N-oxide

Lazertinib Di-N-oxide cost

Lazertinib Di-N-oxide Supplier

Lazertinib Di-N-oxide Distributor

Lazertinib Di-N-oxide for Method Validation

Lazertinib Reference Standard

Lazertinib Di-N-oxide for ANDA Filing

Lazertinib Di-N-oxide for Forced Degradation Studies

Lazertinib Di-N-oxide Identification Standards

Lazertinib Di-N-oxide for DMF Filing

ℹ️

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new developments or findings in product specifications without further notice.

,